Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)
about
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia.Therapy related leukemias: susceptibility, prevention and treatment.Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy.Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients.Arsenic trioxide for the treatment of myelodysplastic syndromes.Emerging drugs for the treatment of myelodysplastic syndrome.Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.Managing myelodysplastic symptoms in elderly patients.Myelodysplastic syndromes: clinical practice guidelines in oncology.Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes.Therapy-related myelodysplasia and acute leukemia.Allogeneic bone marrow transplantation in patients with myelodysplastic syndromes.Myelodysplastic syndromes in childhood--classification, epidemiology, and treatment.Poor prognosis acute myelogenous leukemia.Granulocyte-monocyte and Granulocyte-Colony Stimulating Factors in Myelodysplastic Syndromes.Prognostic implications in myelodysplastic syndromes: A review of 62 cases.Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission.Allogeneic bone marrow transplantation for hematological malignancies--controversies and recent advances.Indications and timing of allogeneic bone marrow transplantation in myelodysplastic syndromes.Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK aTreatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes.Hematopoietic growth factors for the treatment of myelodysplastic syndromes.
P2860
Q33393647-636C904B-10C4-4A0A-B7BF-0740D8D741E1Q33492683-BB6100D6-6FC1-4820-ABCC-B255E53E4593Q34265193-21C712CA-0B15-46AB-8A6E-DDE69FD366BBQ34680950-7B3CE1D9-A70C-404F-88D7-0F537A3FEE78Q34746953-C775A279-CEB0-4F59-8814-5E060765591CQ35688178-A0C2BE7B-94EE-4446-B120-13DFD871FDA2Q36219655-C846BE56-591C-46C9-BA81-81BFE37703E6Q37286248-60633084-85F0-4B95-B644-EE7AA89DF66FQ37448906-B96817C4-E975-4A60-819A-AA3158FB716AQ37723847-3650F0C9-0190-4B99-A641-00664A55A2F8Q39527812-F4BB11AF-0CE4-434C-AE93-C6BE9AB2EC79Q40536765-94629B47-3468-4CD6-91E8-D9261B824765Q40563643-0B0A9071-AB8B-457A-ADB1-1637730B1B44Q40668687-8D7EE37E-DE15-4C5A-9156-7E202F9775D4Q40711700-A991F237-A87D-4AB6-8F84-481510722C59Q41162060-CFDC550E-85D9-456B-9D58-45BF0F673694Q41489340-AE70AB61-548B-4986-8B7B-04A85FF902EBQ41667533-F366877D-978A-46A4-988A-288C06637C5DQ41668011-D1F7E25F-D9B8-4F87-97CD-4E74C5DB9083Q41709002-A5919921-ADD5-438F-8263-5EABEA5A2798Q43653692-D43F76EC-EAB5-400C-A6C8-3FE59E85A5EBQ43666936-42AB04B9-69FC-4640-A325-A08A757B84DAQ43763239-6AB06B7B-B3A4-4C6C-B7A6-55490E973FB2Q44443448-5DACAAB3-E966-48B4-A3D3-438A1BE9D0DEQ45238112-8B463531-0070-4B7D-86A0-BA64DE22230EQ48011127-C06C7177-BD2C-4486-879A-CA4C0C39E194
P2860
Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Allogeneic bone marrow transpl ...... Transplantation Group (EBMTG)
@en
Allogeneic bone marrow transpl ...... e Marrow Transplantation Group
@nl
type
label
Allogeneic bone marrow transpl ...... Transplantation Group (EBMTG)
@en
Allogeneic bone marrow transpl ...... e Marrow Transplantation Group
@nl
prefLabel
Allogeneic bone marrow transpl ...... Transplantation Group (EBMTG)
@en
Allogeneic bone marrow transpl ...... e Marrow Transplantation Group
@nl
P2093
P1476
Allogeneic bone marrow transpl ...... Transplantation Group (EBMTG)
@en
P2093
De Witte T
Lönnqvist B
P304
P356
10.1111/J.1365-2141.1990.TB02558.X
P407
P577
1990-02-01T00:00:00Z